Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy

Open access
Pierce, Lori J., Phillips, Kelly-Anne, Griffith, Kent A., Buys, Saundra, Gaffney, David K., Moran, Meena S., Haffty, Bruce G., Ben-David, Merav, Kaufman, Bella, Garber, Judy E., Merajver, Sofia D., Balmaña, Judith, Meirovitz, Amichay, Domchek, Susan M. · 2010 · Breast Cancer Research and Treatment

Abstract

Women with BRCA1 and BRCA2 mutations have an elevated risk of breast cancer and ovarian cancer, but also of developing second primary breast cancer. BRCA1/2 mutation carriers with breast cancer must choose between breast conservation (BCT) and mastectomy (M) yet data on outcomes are limited. The purpose of this study is to compare long-term outcome following BCT and M in BRCA1/2 carriers. 655 women with BRCA1/2 mutations diagnosed with breast cancer and treated with BCT (n = 302) or M (n = 353) were identified and underwent follow-up to assess local, regional, and systemic recurrence. Local failure as first failure was significantly more likely in those treated with BCT compared to M, with a cumulative estimated risk of 23.5 vs. 5.5%, respectively, at 15 years (P < 0.0001); 15-year estimates in carriers treated with BCT and chemotherapy was 11.9% (P = 0.08 when compared to M). Most events appeared to be second primary cancers rather than failure to control the primary tumor. The risk of contralateral breast cancer was high in all groups, exceeding 40%, but was not statistically significantly different by use of adjuvant radiotherapy (RT) or not, suggesting no added risk from scatter RT at 10 and 15 years. There were no differences seen in regional or systemic recurrences between the BCT and M groups, and no difference in overall survival. In conclusion, BRCA1/2 mutation carriers with breast cancer have similar survival whether treated with M or BCT. However, women undergoing BCT have an elevated risk of a second in-breast event that is significantly reduced in the presence of chemotherapy. Contralateral breast cancer events are very common.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10549-010-0894-z

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 19

  1. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408 · DOI · Paper page
  2. Begg CB, Haile R, Borg A et al (2008) Variation of breast cancer risk amond BRCA1/2 carriers. JAMA 299:194–201
  3. Mann GJ, Thorne H, Balleine RM et al (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12 · DOI
  4. Phillips KA, Milne RL, Buys S et al (2005) Agreement between self-reported breast cancer treatment and medical records in a population-based breast cancer family registry. J Clin Oncol 23:4679–4686 · DOI
  5. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481 · DOI · Paper page
  6. Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 18:695–706 · DOI · Paper page
  7. Pepe M (1991) Inference for events with dependent risks in multiple endpoints studies. J Am Stat Assoc 86:770–778 · DOI · Paper page
  8. Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366:2087–2106 · DOI · Paper page
  9. Schwartz GF, Veronesi U, Clough KB, et al (2006) In: Proceedings on the consensus conference on breast conservation, April 28 to May 2, 2005, Milan, Italy. Cancer 107:242–250 · doi:10.1002/cncr.21988
  10. Turner BC, Harrold E, Matloff E et al (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017–3024 · DOI
  11. Donegan WL, Perez-Mesa CM, Watson FR (1966) A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 122:529–540
  12. Anderson SJ, Wapnir I, Dignam JJ et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473 · DOI · Paper page
  13. Wapnir IL, Anderson SJ, Mamounas EP et al (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028–2037 · DOI · Paper page
  14. Fourquet A, Stoppa-Lyonnet D, Kirova YM et al (2009) Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 32:127–131 · DOI
  15. Kauff ND, Domchek SM, Friebel TM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter prospective study. J Clin Oncol 26:1331–1337 · DOI · Paper page
  16. King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256 · DOI · Paper page
  17. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729 · DOI · Paper page
  18. Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437–2443 · DOI · Paper page
  19. Robson M, Levin D, Federici M et al (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–2117 · DOI · Paper page

Cited by

See all 199

Metadata

Authors
Pierce, L. J., Phillips, K.-A., Griffith, K. A., Buys, S., Gaffney, D. K., Moran, M. S., Haffty, B. G., Ben-David, M., Kaufman, B., Garber, J. E., Merajver, S. D., Balmaña, J., Meirovitz, A., & Domchek, S. M.
Venue
Breast Cancer Research and Treatment
Published
2010-04-22
Volume
121
Issue
2
Pages
389-398
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2073129224
Cited by
199
References
7
FWCI
7.54
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. https://app.cochat.ai/papers/10.1007/s10549-010-0894-z
The paper
Pierce, L. J., Phillips, K.-A., Griffith, K. A., Buys, S., Gaffney, D. K., Moran, M. S., Haffty, B. G., Ben-David, M., Kaufman, B., Garber, J. E., Merajver, S. D., Balmaña, J., Meirovitz, A., & Domchek, S. M. (2010). Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-010-0894-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.